Cancer Treatment Evolution from Traditional Methods to Stem Cells and
Gene Therapy

He, Wenhua; Li, Qingxuan; Lu, Yan; Ju, Dingyue; Gu, Yu; Zhao, Kai; Dong, Chuanming

doi:10.2174/1566523221666211119110755

Cited by 21 publications

(4 citation statements)

References 167 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, gene therapy has emerged as a promising avenue for significantly improving the survival rate of patients with cancer ( 186 ). As aforementioned, the clinical significance and biological functions of SNHG16 may serve as a promising therapeutic target for human digestive system cancer ( Table I ).…”

Section: Discussionmentioning

confidence: 99%

Roles of long non‑coding RNA SNHG16 in human digestive system cancer (Review)

Zhao,

Kan,

Wang

et al. 2024

Oncol Rep

View full text Add to dashboard Cite

The incidence of tumors in the human digestive system is relatively high, including esophageal cancer, liver cancer, pancreatic cancer, gastric cancer and colorectal cancer. These malignancies arise from a complex interplay of environmental and genetic factors. Among them, long non-coding RNAs (lncRNAs), which cannot be translated into proteins, serve an important role in the development, progression, migration and prognosis of tumors. Small nucleolar RNA host gene 16 (SNHG16) is a typical lncRNA, and its relationship with digestive system tumors has been widely explored. The prevailing hypothesis suggests that the principal molecular mechanism of SNHG16 in digestive system tumors involves it functioning as a competitive endogenous RNA that interacts with other proteins, regulates various genes and influences a downstream target molecule. The present review summarizes recent research on the relationship between SNHG16 and numerous types of digestive system cancer, encompassing its biological functions, underlying mechanisms and potential clinical implications. Furthermore, it outlines the association between SNHG16 expression and pertinent risk factors, such as smoking, infection and diet. The present review indicated the promise of SNHG16 as a potential biomarker and therapeutic target in human digestive system cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Roles of long non‑coding RNA SNHG16 in human digestive system cancer (Review)

Zhao,

Kan,

Wang

et al. 2024

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Treating cancer has been a long‐standing concern in the field of medical science. Traditional cancer treatments have limitations that restrict their use, and their side effects can cause significant harm to both the physical and mental health of patients (He et al, 2021) (Table 3). Overcoming these challenges has led to the development of several new approaches for treating tumors, including nanotherapy, immunotherapy, and gene therapy, all aimed at improving patient survival (He et al, 2021).…”

Section: Expanding the Role Of Crispr‐cas9 In Cancer Researchmentioning

confidence: 99%

CRISPR‐Cas9 technology: As an efficient genome modification tool in the cancer diagnosis and treatment

Behrouzian Fard,

Ahmadi,

Gholamin

et al. 2023

Biotech & Bioengineering

View full text Add to dashboard Cite

Cancer is the second most common cause of death globally and is a major public health concern. Managing this disease is difficult due to its multiple stages and numerous genetic and epigenetic changes. Traditional cancer diagnosis and treatment methods have limitations, making it crucial to develop new modalities to combat the increasing burden of cancer. The clustered regularly interspaced short palindromic repeats (CRISPR)‐CRISPR‐associated protein 9 (Cas9) system has transformed genetic engineering due to its simplicity, specificity, low cytotoxicity, and cost‐effectiveness. It has been proposed as an effective technology to enhance cancer diagnosis and treatment strategies. This article presents the most recent discoveries regarding the structure, mechanism, and delivery methods of the highly powerful genome editing tool, CRISPR‐Cas9. In terms of diagnosis, the article examines the role of CRISPR‐Cas9 in detecting microRNAs and DNA methylation, and discusses two popular gene detection techniques that utilize the CRISPR‐Cas system: DNA endonuclease‐targeted CRISPR trans reporter and specific high sensitivity enzymatic reporter unlocking. Regarding treatment, the article explores several genes that have been identified and modified by CRISPR‐Cas9 for effective tumorigenesis of common cancers such as breast, lung, and colorectal cancer. The present review also addresses the challenges and ethical issues associated with using CRISPR‐Cas9 as a diagnostic and therapeutic tool. Despite some limitations, CRISPR‐Cas9‐based cancer diagnosis has the potential to become the next generation of cancer diagnostic tools, and the continuous progress of CRISPR‐Cas9 can greatly aid in cancer treatment.

show abstract

“…Traditional cancer treatment methods (i.e. surgery, radiation, and chemotherapy) have been proven to indiscriminately destroy both normal and malignant cells, resulting in significant toxicities and side effects [1]. The sustained cell proliferation caused by uncontrolled cell division is one of the key pathological manifestations of cancer transformation.…”

Section: Introductionmentioning

confidence: 99%

Targeting Cyclin Dependent Kinase 4/6 for Cancer Therapy

2023

tranc

View full text Add to dashboard Cite

One fundamental hallmark of cancer is uncontrolled cell proliferation. In order to inhibit tumor growth, understanding the mechanisms of disease pathogenesis and the role of cell-cycle regulators which control the division process of cancer cells is necessary, specially CDK4/6, which have been approved as effective therapeutic targets in clinical studies. To date, five CDK4/6 inhibitors have been approved by the U.S. Food and Drug Administration (FDA) and National Medical Products Administration (NMPA). As expected, CDK4/6 inhibitors arrest tumor cells in the G1 phase of the cell cycle. Although undesired, mechanisms of acquired resistance to CDK4/6 inhibitors are beginning to emerge, and extending the use of CDK4/6 inhibitors beyond HR-positive breast cancer is still under consideration and practice. In this assay, we highlight the biological functions of CDK4/6 in the control of cell cycle progression in normal cells and summarize the multiple mechanisms by which the dysregulation of the CDK4/6 pathway of cancer cells. This review also provides a general overview of CDK4/6 inhibitors clinically approved. Instead of monotherapies, combination therapies with CDK inhibitors may especially provide promising results for cancer therapy. We also demonstrate the possible combination with available targeted therapies, immunotherapy, or classical chemotherapy to improve future therapeutic uses of CDK4/6 inhibition in a variety of cancers in clinical trials.

show abstract

Cancer Treatment Evolution from Traditional Methods to Stem Cells and Gene Therapy

Cited by 21 publications

References 167 publications

Roles of long non‑coding RNA SNHG16 in human digestive system cancer (Review)

Roles of long non‑coding RNA SNHG16 in human digestive system cancer (Review)

CRISPR‐Cas9 technology: As an efficient genome modification tool in the cancer diagnosis and treatment

Targeting Cyclin Dependent Kinase 4/6 for Cancer Therapy

Contact Info

Product

Resources

About